Universidade Federal de Minas Gerais (UFMG), Alameda Álvaro Celso 175, Ambulatório Bias Fortes, 2° andar, Belo Horizonte, MG, 30150-260, Brazil.
Universidade Federal de Pernambuco (UFPE), Recife, PE, Brazil.
Adv Rheumatol. 2021 Jan 19;61(1):4. doi: 10.1186/s42358-020-00160-6.
Spondyloarthritis (SpA) is a group of chronic inflammatory systemic diseases characterized by axial and/or peripheral joints inflammation, as well as extra-articular manifestations. Over some decades, nonsteroidal anti-inflammatory drugs (NSAIDs) have been the basis for the pharmacological treatment of patients with axial spondyloarthritis (axSpA). However, the emergence of the immunobiologic agents brought up the discussion about the role of NSAIDs in the management of these patients. The objective of this guideline is to provide recommendations for the use of NSAIDs for the treatment of axSpA. A panel of experts from the Brazilian Society of Rheumatology conducted a systematic review and meta-analysis of randomized clinical trials for 15 predefined questions. The Grading of Recommendations, Assessment, Development and Evaluation methodology to assess the quality of evidence and formulate recommendations were used, and at least 70% agreement of the voting panel was needed. Fourteen recommendations for the use of NSAIDs in the treatment of patients with axSpA were elaborated. The purpose of these recommendations is to support clinicians' decision making, without taking out his/her autonomy when prescribing for an individual patient.
脊柱关节炎(SpA)是一组以中轴和/或外周关节炎症以及关节外表现为特征的慢性炎症性系统性疾病。几十年来,非甾体抗炎药(NSAIDs)一直是治疗中轴型脊柱关节炎(axSpA)患者的药物治疗基础。然而,免疫生物制剂的出现引发了关于 NSAIDs 在这些患者管理中作用的讨论。本指南的目的是为 NSAIDs 治疗 axSpA 提供使用建议。巴西风湿病学会的专家组针对 15 个预先确定的问题进行了系统评价和荟萃分析。使用了推荐分级的评估、制定与评价(Grading of Recommendations, Assessment, Development and Evaluation)方法来评估证据质量并制定建议,需要投票小组至少 70%的一致意见。制定了 14 条 NSAIDs 在 axSpA 患者治疗中的使用建议。这些建议的目的是支持临床医生的决策制定,同时在为个体患者开处方时不剥夺其自主权。